TR201910177T4 - Bir sinakalset HCl içeren hızlı çözünme formülasyonu. - Google Patents

Bir sinakalset HCl içeren hızlı çözünme formülasyonu. Download PDF

Info

Publication number
TR201910177T4
TR201910177T4 TR2019/10177T TR201910177T TR201910177T4 TR 201910177 T4 TR201910177 T4 TR 201910177T4 TR 2019/10177 T TR2019/10177 T TR 2019/10177T TR 201910177 T TR201910177 T TR 201910177T TR 201910177 T4 TR201910177 T4 TR 201910177T4
Authority
TR
Turkey
Prior art keywords
formulation containing
fast dissolution
cinacalcet hcl
pharmaceutical composition
dissolution formulation
Prior art date
Application number
TR2019/10177T
Other languages
English (en)
Inventor
J Álvarez Francisco
R Ju Tzuchi
H Lin Hung-Ren
Cary Lawrence Glen
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34434844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR201910177(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of TR201910177T4 publication Critical patent/TR201910177T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Mevcut buluş, terapötik olarak etkili bir miktarda kalsiyum reseptör-aktif bileşiği ve en az bir farmasötik olarak kabul edilebilir eksipiyanı içeren farmasötik bir bileşim ile ilgilidir, burada bileşim, kontrollü bir çözünme profiline sahiptir. Mevcut buluş ayrıca, farmasötik bileşimi üretme yöntemi ve farmasötik bileşimin kullanıldığı hastalığı tedavi etme yöntemi ile ilgilidir.
TR2019/10177T 2003-09-12 2004-09-10 Bir sinakalset HCl içeren hızlı çözünme formülasyonu. TR201910177T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50221903P 2003-09-12 2003-09-12

Publications (1)

Publication Number Publication Date
TR201910177T4 true TR201910177T4 (tr) 2019-08-21

Family

ID=34434844

Family Applications (4)

Application Number Title Priority Date Filing Date
TR2019/10447T TR201910447T4 (tr) 2003-09-12 2004-09-10 Sinakalset HCI'nin hızlı çözünme formülasyonu.
TR2019/10177T TR201910177T4 (tr) 2003-09-12 2004-09-10 Bir sinakalset HCl içeren hızlı çözünme formülasyonu.
TR2019/10180T TR201910180T4 (tr) 2003-09-12 2004-09-10 Sinakalset HCI'nin hızlı çözünme formülasyonu.
TR2019/09267T TR201909267T4 (tr) 2003-09-12 2004-09-10 Sinakalset HCl içeren hızlı çözünme formülasyonu.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TR2019/10447T TR201910447T4 (tr) 2003-09-12 2004-09-10 Sinakalset HCI'nin hızlı çözünme formülasyonu.

Family Applications After (2)

Application Number Title Priority Date Filing Date
TR2019/10180T TR201910180T4 (tr) 2003-09-12 2004-09-10 Sinakalset HCI'nin hızlı çözünme formülasyonu.
TR2019/09267T TR201909267T4 (tr) 2003-09-12 2004-09-10 Sinakalset HCl içeren hızlı çözünme formülasyonu.

Country Status (30)

Country Link
US (7) US7829595B2 (tr)
EP (8) EP3395338B1 (tr)
JP (3) JP5026077B2 (tr)
KR (1) KR101332058B1 (tr)
CN (1) CN1946382B (tr)
AR (1) AR045637A1 (tr)
AU (1) AU2004279318C1 (tr)
BR (2) BR122018013029B1 (tr)
CA (1) CA2536487C (tr)
CY (5) CY1119609T1 (tr)
DE (1) DE19164145T1 (tr)
DK (6) DK3260117T3 (tr)
EA (1) EA013425B1 (tr)
ES (7) ES2735226T3 (tr)
HR (1) HRP20130114T4 (tr)
HU (5) HUE045411T2 (tr)
IL (1) IL173737A (tr)
IS (1) IS3027B (tr)
MX (1) MXPA06002616A (tr)
MY (1) MY142046A (tr)
NO (1) NO335739B1 (tr)
NZ (1) NZ545498A (tr)
PL (6) PL1663182T5 (tr)
PT (6) PT2821067T (tr)
SG (1) SG146608A1 (tr)
SI (6) SI3395340T1 (tr)
TR (4) TR201910447T4 (tr)
TW (1) TWI344363B (tr)
WO (1) WO2005034928A1 (tr)
ZA (1) ZA200602710B (tr)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100074949A1 (en) * 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
DK3260117T3 (da) 2003-09-12 2019-07-01 Amgen Inc Hurtigt opløsende formulering, der omfatter cinacalcet-hcl
CN101006076B (zh) 2004-06-24 2010-09-29 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的调控剂
ATE443038T1 (de) * 2005-05-16 2009-10-15 Teva Pharma Verfahren zur herstellung von cinacalcet hydrochlorid
JP2008507565A (ja) * 2005-05-23 2008-03-13 テバ ファーマシューティカル インダストリーズ リミティド シナカルセトの精製
KR20080007376A (ko) * 2005-05-23 2008-01-18 테바 파마슈티컬 인더스트리즈 리미티드 무정형 시나칼셋 염산염 및 이의 제조
BRPI0611409B8 (pt) 2005-05-26 2021-05-25 Dainippon Sumitomo Pharma Co preparação oral compreendendo lurasidona
JP5244597B2 (ja) * 2005-09-02 2013-07-24 アムジエン・インコーポレーテツド カルシリティック化合物またはカルシウム模倣性化合物を用いて腸液バランスを調節する方法
WO2007062147A1 (en) * 2005-11-22 2007-05-31 Teva Pharmaceutical Industries Ltd. Crystal forms of cinacalcet hci and processes for their preparation
JP5409010B2 (ja) 2005-12-28 2014-02-05 バーテックス ファーマシューティカルズ インコーポレイテッド Ｎ−［２，４−ビス（１，１−ジメチルエチル）−５−ヒドロキシフェニル］−１，４−ジヒドロ−４−オキソキノリン−３−カルボキサミドの固体形態
US8426391B2 (en) 2006-02-03 2013-04-23 Proventiv Therapeutics, Llc Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3
EP2001832A1 (en) * 2006-03-23 2008-12-17 Amgen Inc. Methods and compositions for making and using polymorphs of cinacalcet
KR20080011320A (ko) * 2006-04-27 2008-02-01 테바 파마슈티컬 인더스트리즈 리미티드 시나칼셋 염기의 제조 방법
CA2649616A1 (en) * 2006-04-27 2007-11-08 Teva Pharmaceutical Industries Ltd. Process for the preparation of cinacalcet base
SI2679228T1 (en) 2006-06-21 2018-06-29 Opko Ireland Global Holdings, Ltd. THERAPY WITH THE USE OF VITAMIN D ADDITIONAL FIBER AND HORMON RESISTANCE OF VITAMIN D
US20090258949A1 (en) * 2006-06-27 2009-10-15 Johannes Ludescher Amorphous form of cinacalcet
US20080181959A1 (en) * 2006-09-01 2008-07-31 Ilan Zalit Solid composites of a calcium receptor-active compound
US20080146845A1 (en) * 2006-11-20 2008-06-19 Boaz Gome Process for preparing Cinacalcet
WO2008064202A2 (en) * 2006-11-20 2008-05-29 Dr. Reddy's Labortories, Ltd. Modified-release formulations of calcium receptor-active compounds
TWI573802B (zh) 2007-03-06 2017-03-11 安美基公司 變異之活動素受體多肽及其用途
CA2701638A1 (en) * 2007-04-02 2008-10-09 Concert Pharmaceuticals Inc. Pharmaceutical calcimimetics
ES2403107T3 (es) 2007-04-25 2013-05-14 Cytochroma Inc. Método de tratamiento de insuficiencia y deficiencia de vitamina D
DK3342405T3 (da) 2007-04-25 2019-11-11 Opko Ireland Global Holdings Ltd Kontrolleret frigivelse af 25-hydroxyvitamin d
EP2170805B1 (en) 2007-06-21 2016-03-16 Amgen Inc. Methods of synthesizing cinacalcet and salts thereof
WO2009025792A2 (en) * 2007-08-16 2009-02-26 Teva Pharmaceutical Industries Ltd. Crystalline forms cinacalcet fumarate and cinacalcet succinate and processes for preparation thereof
EP2300415A2 (en) * 2008-05-05 2011-03-30 Medichem, S.A. Process for controlling the particle size of a 3-(trifluoromethyl)phenyl¨-1-aminopropane derivative
US20100256184A1 (en) * 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
JP2012503613A (ja) * 2008-09-25 2012-02-09 ラシオファルム ゲーエムベーハー コンパクト化シナカルセット
WO2010086129A1 (en) 2009-01-27 2010-08-05 Rathiopharm Gmbh Inclusion complex comprising cinacalcet and cyclodextrin
EP2821400B1 (en) 2009-03-20 2017-09-27 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
JP2012528084A (ja) 2009-05-27 2012-11-12 レオ ファーマ アクティーゼルスカブ 新規のカルシウム感知受容体調節化合物およびその医薬用途
EP2435404A1 (en) 2009-05-27 2012-04-04 Leo Pharma A/S Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
EP2314286A1 (de) 2009-10-21 2011-04-27 Ratiopharm GmbH Schmelzgranuliertes Cinacalcet
EP3636280A1 (en) 2010-03-29 2020-04-15 Opko Ireland Global Holdings, Ltd. Methods and compositions for reducing parathyroid levels
CN109745313A (zh) 2010-08-11 2019-05-14 德雷克塞尔大学 治疗帕金森病中运动障碍的d3多巴胺受体激动剂
WO2012071535A2 (en) * 2010-11-23 2012-05-31 Amgen Inc Pediatric formulation
CN103228619A (zh) 2010-11-26 2013-07-31 利奥制药有限公司 钙传感受体活性化合物
JP2014507375A (ja) 2010-11-26 2014-03-27 レオ ファーマ アクティーゼルスカブ カルシウム感知受容体活性化合物
WO2012069419A1 (en) 2010-11-26 2012-05-31 Leo Pharma A/S Calcium-sensing receptor-active compounds
WO2012069402A1 (en) 2010-11-26 2012-05-31 Leo Pharma A/S Substituted cyclopentyl - azines as casr- active compounds
MX358358B (es) 2011-12-19 2018-08-15 Amgen Inc Polipeptidos de receptores de activina variantes y sus usos.
WO2013107503A1 (en) 2012-01-17 2013-07-25 Zentiva Saglik Urunleri San. Ve Tic. A.S. Method for producing cinacalcet compositions for direct tableting
MX2014010253A (es) 2012-02-27 2014-11-12 Vertex Pharma Composicion farmaceutica y administraciones de la misma.
CN102885792A (zh) * 2012-10-12 2013-01-23 华润赛科药业有限责任公司 盐酸西那卡塞的口服固体速释制剂
PL2730279T3 (pl) * 2012-11-09 2015-12-31 K H S Pharma Holding Gmbh Preparaty cynakalcetu o natychmiastowym uwalnianiu
HUE051406T2 (hu) 2012-11-14 2021-03-01 Grace W R & Co Biológiailag aktív anyagot és rendezetlen szervetlen oxidot tartalmazó kompozíciók
CA2895881C (en) * 2012-12-21 2020-03-31 Synthon B.V. Tablet composition comprising cinacalcet hydrochloride
MX2015009901A (es) 2013-02-01 2016-04-06 Santa Maria Biotherapeutics Inc Administración de un compuesto de antiactivina a a un sujeto.
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
WO2014207691A1 (en) 2013-06-26 2014-12-31 Jubilant Life Sciences Limited Disintegrant free composition of cinacalcet
EP3116487A1 (en) 2014-03-14 2017-01-18 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Pharmaceutical composition of cinacalcet
WO2015150944A1 (en) 2014-03-29 2015-10-08 Wockhardt Limited Solid oral pharmaceutical compositions comprising cinacalcet or a salt thereof
SG10201911274TA (en) * 2014-08-07 2020-02-27 Opko Ireland Global Holdings Ltd Adjunctive therapy with 25-hydroxyvitamin d
WO2016057730A1 (en) 2014-10-07 2016-04-14 Strohmeier Mark Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
CN104721164B (zh) * 2015-03-25 2017-07-07 河北仁合益康药业有限公司 一种盐酸西那卡塞薄膜衣片组合物
SG10201913863TA (en) 2016-03-28 2020-03-30 Opko Ireland Global Holdings Limited Methods of vitamin d treatment
KR20180125574A (ko) 2016-03-31 2018-11-23 인터셉트 파마슈티컬즈, 인크. 용출성이 우수한 경구 제제
WO2019034981A1 (en) * 2017-08-16 2019-02-21 Unichem Laboratories Ltd PHARMACEUTICAL COMPOSITIONS COMPRISING CINACALCET CHLORHYDRATE AND ONE OR MORE BINDERS
WO2019186516A1 (en) 2018-03-30 2019-10-03 Ftf Pharma Private Limited Liquid dosage forms of cinacalcet or salt thereof
US10920483B2 (en) 2018-10-25 2021-02-16 Mark Mutchnik Window seal for preventing water penetration
RU2750761C2 (ru) * 2019-09-17 2021-07-02 Общество с ограниченной ответственностью "АМЕДАРТ" Ядро таблетки, содержащей цинакальцета гидрохлорид
CN115666534A (zh) * 2020-02-29 2023-01-31 肯法姆股份有限公司 包含哌甲酯前药的组合物、其制备和使用方法
CN112546010A (zh) * 2020-12-02 2021-03-26 普莱赛思(天津)生命科技有限公司 一种肾病药物组合物及其制备方法

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4517179A (en) 1983-04-29 1985-05-14 Pennwalt Corporation Rapid dissolving, uniform drug compositions and their preparation
EP0315249A1 (en) 1987-11-02 1989-05-10 Merck & Co. Inc. Phthalazineacetic acid composition and tablet
EP0357815A1 (de) 1988-09-06 1990-03-14 Siemens Aktiengesellschaft Schaltbare Konstantstromquelle mit I2L-Gattern
IL92484A0 (en) 1988-11-30 1990-08-31 Schering Corp Sustained release diltiazem formulation
NZ231897A (en) * 1988-12-30 1992-09-25 Monsanto Co Dry water-soluble granular composition comprising glyphosate and a liquid surfactant
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US4931286A (en) 1989-04-19 1990-06-05 Aqualon Company High gloss cellulose tablet coating
DD299322A5 (de) * 1989-09-21 1992-04-09 Maschinenfabrik Rieter Ag,Ch Verfahren und vorrichtung zur feinreinigung von textilfasern
US5011068A (en) * 1989-12-05 1991-04-30 Progressive Tool & Industries Co. Automotive body framing system
US6031003A (en) 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6001884A (en) * 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6011068A (en) 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
EP0724561B1 (en) 1991-08-23 2004-04-14 Nps Pharmaceuticals, Inc. Calcium receptor-active arylalkyl amines
JP2728564B2 (ja) 1991-08-23 1998-03-18 エヌピーエス・ファーマシウティカルズ・インコーポレイテッド カルシウム受容体活性化分子
US6313146B1 (en) * 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5162117A (en) 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
DE69333527T2 (de) 1993-02-23 2005-06-16 Brigham & Women's Hospital, Inc., Boston Calciumrezeptoraktive moleküle
US6210714B1 (en) * 1993-11-23 2001-04-03 Euro-Celtique S.A. Immediate release tablet cores of acetaminophen having sustained-release coating
UA41909C2 (uk) * 1994-07-22 2001-10-15 Елі Ліллі Енд Компані Використання комбінації сполук для інгібірування остеопорозу, фармацевтичний препарат
ATE287390T1 (de) * 1994-10-21 2005-02-15 Nps Pharma Inc Kalzium-rezeptor aktive verbindungen
GB9424766D0 (en) 1994-12-07 1995-02-08 Wellcome Found Pharmaceutical composition
GB9501127D0 (en) 1995-01-20 1995-03-08 Wellcome Found Tablet
DE19530575A1 (de) 1995-08-19 1997-02-20 Gruenenthal Gmbh Schnell zerfallende Arzneiform von Tramadol oder einem Tramadolsalz
ATE430123T1 (de) 1996-05-01 2009-05-15 Nps Pharma Inc Inorganische am ionen-rezeptor aktive verbindungen
US5837292A (en) * 1996-07-03 1998-11-17 Yamanouchi Europe B.V. Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug
US6362231B1 (en) * 1996-07-08 2002-03-26 Nps Pharmaceuticals, Inc. Calcium receptor active compounds
DE19637082A1 (de) 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Schnellzerfallende Pellets
TW483881B (en) 1996-12-03 2002-04-21 Nps Pharma Inc Calcilytic compounds
IE970588A1 (en) * 1997-08-01 2000-08-23 Elan Corp Plc Controlled release pharmaceutical compositions containing tiagabine
WO1999009458A1 (de) 1997-08-13 1999-02-25 OCé PRINTING SYSTEMS GMBH Druck- oder kopiergerätesystem zum performanceangepassten erstellen einer vorgegebenen blattfolge von monochrom und/oder farbig bedruckten einzelblättern
AU741992B2 (en) 1998-03-06 2001-12-13 Adare Pharmaceuticals S.R.L. Fast disintegrating tablets
US6525084B2 (en) 1998-07-23 2003-02-25 Novo Nordisk A/S Stable pharmaceutical formulation
CA2347092A1 (en) 1998-10-14 2000-04-20 Ortho-Mcneil Pharmaceutical, Inc. 1,2-disubstituted cyclopropanes
BR9915566B1 (pt) * 1998-11-23 2011-11-01 composição herbicida e processo herbicida.
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6447809B1 (en) * 1999-05-11 2002-09-10 Metagenics, Inc. Composition for promoting healthy bone structure
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
FR2800735B1 (fr) 1999-11-09 2002-02-01 Centre Nat Rech Scient Nouvelles aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation
MXPA02006150A (es) * 1999-12-22 2004-09-06 Pharmacia Corp Formulaciones de liberacion sostenida de un inhibidor de ciclooxigenasa-2.
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
AU5066101A (en) * 2000-04-13 2001-10-30 Synthon B.V. Modified release formulations containing a hypnotic agent
US6419954B1 (en) * 2000-05-19 2002-07-16 Yamanouchi Pharmaceutical Co., Ltd. Tablets and methods for modified release of hydrophilic and other active agents
FR2809396B1 (fr) 2000-05-24 2005-10-14 Centre Nat Rech Scient Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
US6656492B2 (en) * 2000-06-30 2003-12-02 Yamanouchi Pharmaceutical Co., Ltd. Quick disintegrating tablet in buccal cavity and manufacturing method thereof
US20040034039A1 (en) 2000-09-22 2004-02-19 Yoshinori Nakano Solid preparations
JP2002167327A (ja) * 2000-09-22 2002-06-11 Takeda Chem Ind Ltd 固形製剤
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
IN191028B (tr) * 2001-05-17 2003-09-13 Sun Pharmaceutical Ind Ltd
BR0210520A (pt) 2001-06-22 2004-06-22 Pfizer Prod Inc Composições farmacêuticas de dispersões de fármacos amorfos misturados com polìmeros
EP1321142A1 (en) 2001-12-21 2003-06-25 Novartis AG Solid pharmaceutical composition for oral administration of Tegaserod
WO2003086343A2 (en) 2002-04-05 2003-10-23 Cadila Healthcare Limited Fast disintegrating oral dosage forms
US20050147670A1 (en) * 2002-05-29 2005-07-07 Impax Laboratories Inc. Oral disintegrating dosage forms
TW200412956A (en) 2002-09-30 2004-08-01 Schering Corp Methods for treating disorders of calcium homeostasis
GB0230015D0 (en) 2002-12-23 2003-01-29 Novartis Ag Organic compounds
DK3260117T3 (da) 2003-09-12 2019-07-01 Amgen Inc Hurtigt opløsende formulering, der omfatter cinacalcet-hcl
JP4559431B2 (ja) 2004-08-23 2010-10-06 テバ ファーマシューティカル インダストリーズ リミティド 固体及び結晶イバンドロネートナトリウム及びその調製方法
NL1028867C2 (nl) 2005-04-26 2006-10-27 Xycarb Ceramics B V Inrichting voor het ondersteunen van een substraat alsmede een werkwijze voor het vervaardigen van een dergelijke inrichting.
WO2009111876A1 (en) 2008-03-11 2009-09-17 The University Of Western Ontario System and method for magnetic resonance imaging

Also Published As

Publication number Publication date
JP5849015B2 (ja) 2016-01-27
SI2821067T1 (en) 2018-03-30
AR045637A1 (es) 2005-11-02
EP3578175B1 (en) 2022-11-30
SI3395338T1 (sl) 2019-08-30
MY142046A (en) 2010-08-30
DK3395338T3 (da) 2019-07-22
HRP20130114T4 (hr) 2019-12-27
HUE043958T2 (hu) 2019-09-30
KR20070017460A (ko) 2007-02-12
EP2821067A1 (en) 2015-01-07
US20110136915A1 (en) 2011-06-09
HUE035596T2 (en) 2018-05-28
PL3395339T3 (pl) 2019-09-30
EP3395340B1 (en) 2019-04-17
EP3395338A1 (en) 2018-10-31
ES2734057T3 (es) 2019-12-04
AU2004279318C1 (en) 2020-06-25
EP1663182B2 (en) 2019-11-20
CY1121812T1 (el) 2020-07-31
EA200600566A1 (ru) 2006-08-25
EP3260117A1 (en) 2017-12-27
CY1119609T1 (el) 2018-04-04
NZ545498A (en) 2010-04-30
TWI344363B (en) 2011-07-01
KR101332058B1 (ko) 2013-11-22
MXPA06002616A (es) 2006-06-05
EA013425B1 (ru) 2010-04-30
US20050147669A1 (en) 2005-07-07
IL173737A0 (en) 2006-07-05
DK3395340T3 (da) 2019-07-15
JP5940120B2 (ja) 2016-06-29
EP3395340A1 (en) 2018-10-31
JP2015007089A (ja) 2015-01-15
DK3260117T3 (da) 2019-07-01
CN1946382B (zh) 2010-12-08
EP3395339A1 (en) 2018-10-31
JP2007505108A (ja) 2007-03-08
PL3260117T3 (pl) 2019-10-31
WO2005034928A1 (en) 2005-04-21
CY1121814T1 (el) 2020-07-31
ZA200602710B (en) 2007-04-25
US7829595B2 (en) 2010-11-09
IS3027B (is) 2021-03-15
BRPI0414254B8 (pt) 2021-05-25
US20190117592A1 (en) 2019-04-25
AU2004279318A1 (en) 2005-04-21
PT3395340T (pt) 2019-07-15
US20210052518A1 (en) 2021-02-25
DK2821067T3 (en) 2017-12-04
HRP20130114T1 (en) 2013-03-31
HUE045411T2 (hu) 2019-12-30
AU2004279318B2 (en) 2010-02-25
BRPI0414254B1 (pt) 2021-03-02
SI3260117T1 (sl) 2019-08-30
TR201910180T4 (tr) 2019-07-22
ES2737348T3 (es) 2020-01-13
BR122018013029B1 (pt) 2022-04-12
BRPI0414254A (pt) 2006-11-07
CY1121820T1 (el) 2020-07-31
ES2401769T5 (es) 2020-07-01
ES2735226T3 (es) 2019-12-17
PT3395338T (pt) 2019-07-23
SI1663182T1 (sl) 2013-05-31
JP5026077B2 (ja) 2012-09-12
EP3395339B8 (en) 2019-12-11
SI3395340T1 (sl) 2019-08-30
EP1663182A1 (en) 2006-06-07
CN1946382A (zh) 2007-04-11
CA2536487A1 (en) 2005-04-21
SI3395339T1 (sl) 2019-08-30
PL2821067T3 (pl) 2018-02-28
EP3395340B8 (en) 2019-12-11
CY1122259T1 (el) 2020-11-25
TW200518743A (en) 2005-06-16
PT3260117T (pt) 2019-07-04
EP2821067B1 (en) 2017-10-25
ES2812198T1 (es) 2021-03-16
NO20061640L (no) 2006-06-12
NO335739B1 (no) 2015-02-02
HUE044822T2 (hu) 2019-11-28
DK1663182T4 (da) 2020-02-17
US20160338975A1 (en) 2016-11-24
CA2536487C (en) 2011-10-25
PL1663182T5 (pl) 2020-07-27
ES2735216T3 (es) 2019-12-17
EP3395338B1 (en) 2019-05-01
IL173737A (en) 2012-04-30
US20200222340A1 (en) 2020-07-16
EP3260117B1 (en) 2019-04-17
TR201909267T4 (tr) 2019-07-22
EP3260117B8 (en) 2019-11-27
PL3395338T3 (pl) 2019-10-31
EP2316442A1 (en) 2011-05-04
PL3395340T3 (pl) 2019-10-31
PL1663182T3 (pl) 2013-06-28
ES2655435T3 (es) 2018-02-20
ES2401769T3 (es) 2013-04-24
HUE044279T2 (hu) 2019-10-28
EP1663182B1 (en) 2013-01-16
EP3578175A1 (en) 2019-12-11
SG146608A1 (en) 2008-10-30
DK1663182T3 (da) 2013-04-15
PT3395339T (pt) 2019-07-15
DK3395339T3 (da) 2019-07-22
PT2821067T (pt) 2017-12-01
DE19164145T1 (de) 2021-04-29
US20180243238A1 (en) 2018-08-30
PT1663182E (pt) 2013-03-14
EP3395339B1 (en) 2019-04-17
JP2012197280A (ja) 2012-10-18
US9375405B2 (en) 2016-06-28
SI1663182T2 (sl) 2020-02-28
TR201910447T4 (tr) 2019-08-21
IS8324A (is) 2006-02-23

Similar Documents

Publication Publication Date Title
TR201910177T4 (tr) Bir sinakalset HCl içeren hızlı çözünme formülasyonu.
PL372809A1 (en) Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof
BRPI0413393A (pt) fexofenadina, composição farmaceuticamente aceitável, método de tratamento antihistamìnico, composição, processo para preparar fexofenadina e uso de fexofenadina
ATE355829T1 (de) Einen lipophilen wirkstoff enthaltende feste pharmazeutische zusammensetzung sowie deren herstellung
ATE505203T1 (de) Pharmazeutische kombination aus aliskiren und valsartan
ZA200806778B (en) N-Hydroxyacrylamide compounds
BRPI0517032A (pt) compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades e utilização desses compostos
AR038618A1 (es) Forma poliformica cristalina de clorhidratos de irinotecan
BR0315462A (pt) Composto, composição farmacêutica, uso de um composto, método para o tratamento de um sujeito que sofre de uma condição patológica ou de doença susceptìvel de alìvio por antagonismo de receptores de ltd4 e produto de combinação
SE0102440D0 (sv) New compound
DOP2003000621A (es) Inhibidores triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa
AR039162A1 (es) Formulaciones de venlafaxina de liberacion extendida
BRPI0507985A (pt) derivados de piperazina uréia para o tratamento de endometriose
MXPA01009032A (es) Composicion farmaceutica para la prevencion o el tratamiento de una enfermedad asociada con un exceso se la produccion de il-12.
CY1113703T1 (el) Ταχειας διαλυσης φαρμακοτεχνικη μορφη της σινακαλσετης hci
DE60102084D1 (de) Propanolaminotetraline, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende pharmazeutische zusammensetzungen
DE50202121D1 (de) Metallsalze als antimykotika
CR7754A (es) Derivados de 4-piridil-metil-ftalazina para la fabricacion de un medicamento para el tratamiento de sindromes mielodisplasticos
BRPI0414423A (pt) inibidores de pace4, suas composições farmacêuticas e respectivos usos
GR1004660B (el) Βελτιωμενες φαρμακευτικες συνθεσεις του τριυδρικου αλενδρονικου νατριου και μεθοδοι παρασκευης τους
RU2004107084A (ru) Способ лечения рецидивирующего птеригиума
CY1110563T1 (el) Παραγωγο του ισοξαζολικου οξεος για την ανακουφιση νευροπαθητικου πονου
UY27599A1 (es) Formulaciones de acitromicina directamente compresibles